Supplementary Tables S1-S19 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer
Authors: Hedayat Somaieh , Cascione Luciano , Cunningham David , Schirripa Marta , Lampis Andrea , Hahne Jens C. , Tunariu Nina , Hong Sung Pil , Marchetti Silvia , Khan Khurum , Fontana Elisa , Angerilli Valentina , Delrieux Mia , Nava Rodrigues Daniel , Procaccio Letizia , Rao Sheela , Watkins David , Starling Naureen , Chau Ian , Braconi Chiara , Fotiadis Nicos , Begum Ruwaida , Guppy Naomy , Howell Louise , Valenti Melanie , Cribbes Scott , Kolozsvari Bernadett , Kirkin Vladimir , Lonardi Sara , Ghidini Michele , Passalacqua Rodolfo , Elghadi Raghad , Magnani Luca , Pinato David J. , Di Maggio Federica , Ghelardi Filippo , Sottotetti Elisa , Vetere Guglielmo , Ciracì Paolo , Vlachogiannis Georgios , Pietrantonio Filippo , Cremolini Chiara , Cortellini Alessio , Loupakis Fotios , Fassan Matteo , Valeri Nicola 
Published: May 2024

<p>Supplementary Table S1. Clinical characteristics of the cohorts used in the circulating biomarker analysis
Supplementary Table S2. Cox proportional hazard regression analysis for miRNAs whose deregulation is associated with PFS
Supplementary Table S3. Cox proportional hazard regression analysis for miRNAs whose deregulation is associated with OS
Supplementary Table S4A. Multivariate Analysis of Factors Affecting Progression Free Survival in the PROSPECT-R Trial
Supplementary Table S4B. Multivariate Analysis of Factors Affecting Overall Survival in the PROSPECT-R Trial
Supplementary Table S5. Associaiton between MIR652-3p expression and overall response rate (ORR) in the PROSPECT-R Trial
Supplementary Table S6. Toxicity, dose reductions and treatment discontinuation
Supplementary Table S7. Backward stepwise selection of covariate for the pooled analysis.
Supplementary Table S8. MVA prognostic model based on known prognostic features in patients treated with regorafenib.
Supplementary Table S9. Comparison between MIR652-3p expression by ISH and by RT-PCR in tissues from patients enrolled in the PROSPECT-R Trial
Supplementary Table S10. Response after 8 weeks of treatment according to MIR652-3p ISH score in the PROSPECT-R Trial
Supplementary Table S11. Comparison between MIR652-3p expression in tissue versus liquid biopses in tissues from patients enrolled in the PROSPECT-R Trial
Supplementary Table S12. Clinical-pathological features of the PDO biobank
Table S13. List of deregulated genes in the comparison between treated and untreated EC cells grown in the 1021BL co-culture
Table S14. List of deregulated genes in the comparison between EC cells grown in the 1021BL Versus the 1021PD co-culture
Table S15. List of deregulated genes in the comparison between treated and untreated CAFs grown in the 1021BL co-culture
Table S16. List of deregulated genes in the comparison between treated and untreated PDOs grown in the 1021BL co-culture
Table S17. List of deregulated genes in the comparison between PDOs grown in the 1021BL Versus the 1021PD co-culture
Table S18. List of deregulated genes in the comparison between CAFs grown in the 1021BL Versus the 1021PD co-culture
Table S19. List of deregulated genes in the comparioson between 1021BL MIR623-3p over-expressing PDOs and relative contorls</p>